Carvelli et al, 2022.
Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE])
Critical Care Medicine
Innate Pharma 2023 financial calendar
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today released its 2023 financial calendar: March 23, 2023: Publication of 2022 financial statements May 10, 2023...
Demaria et al, 2022.
Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant
Cell Reports Medicine
Innate Pharma presents data from ongoing Phase 2 TELLOMAK trial demonstrating clinical activity of lacutamab in advanced mycosis fungoides
Preliminary data set presented at EORTC CLTG annual meeting confirms clinical activity and favorable safety profile of lacutamab in patients with mycosis fungoides who express KIR3DL2 and who were...
Colomar-Carando et al, 2022.
Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia
Cancer Immunol Res.
Innate Pharma reports first half 2022 financial results and business update
Monalizumab and IPH5201 developed in collaboration with AstraZeneca advanced into Phase 3 and 2 clinical trials in lung cancer, triggering $55M in milestone payments Second preclinical asset based on...
Innate Pharma announces conference call and webcast for first half 2022 business update
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announced that the Company will hold a conference call on Thursday, September 15, 2022, at 2 p.m. CEST / 8 a...
Chiossone, Vivier et al, 2022.
Bringing natural killer cells to the clinic
J Exp Med.
Innate Pharma to present lacutamab PTCL Phase 1b design and ANKET platform at ESMO 2022
Poster presentation on ongoing lacutamab Phase 1b trial design in monotherapy in peripheral T-cell lymphoma Oral presentation on multispecific antibodies: ANKET for antigen-specific activation of NK...
Innate Pharma to participate in upcoming investor conferences
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its senior management team are scheduled to participate in the following upcoming...